Navigation Links
QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System
Date:7/28/2009

uates the effect of artificial tears preserved with benzalkonium chloride (AT-BAK) on IOP response to L-PPDS; 22 patients are currently enrolled and enrollment is continuing. The second trial compares IOP and safety outcomes based on L-PPDS placement (upper or lower punctum); enrollment is complete with 30 patients, and follow-up is ongoing.

The Device Study (Punctal Plug Prototype Designs)

This study is an ongoing, device, open-label, multicenter study conducted to investigate the safety, tolerability, comfort, ease of handling and insertion/removal, and retention of punctal plug prototype designs, in healthy subjects. Subjects are fitted with a punctal plug in each eye and wear the devices for 24 hours, after which the plugs are removed and replaced. Subjects then wear the devices for up to 12 weeks. Enrollment is ongoing. The preliminary overall retention rate of 75% after eight weeks of follow-up is based on a baseline sample of 447 eyes from 239 subjects who were fitted with prototypes from one family of designs. Subject comfort ratings for this design family are high (mean of 97 on a scale of 0-100 at Week 8), and physician handling assessments indicate that the devices are easy to insert and remove. Interim analyses show that these designs have been well tolerated. The most frequently reported adverse events for subjects fit with this family of designs have been increased lacrimation, eye irritation, and device migration (2.1% for each event); conjunctival hyperemia (1.7%); and conjunctival edema and eye disorder (1.3% for each event). Interim analyses of all punctal plug prototype designs in 590 subjects show that the most frequently reported adverse events overall have been device migration (3.7%), conjunctival hyperemia (1.3%), and eye irritation (1.0%).

Prototype punctal plug designs continue to be refined and evaluated to meet our retention criteria and converge with the identification of a dose formulation to pr
'/>"/>

SOURCE QLT Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. QLT Announces Second Quarter Results for 2009
2. MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage
3. Grupo Casa Saba Announces Quarterly Earnings Report 2Q09
4. Image Sensors 2009 Announces Final Program and New Interactive Brochure
5. ULURU Inc. Announces Status of York Note Receivable
6. Danaher Corporation Announces Retirement of Executive Vice President Philip W. Knisely
7. Paradigm Spine Closes $21.5 Million Financing and Announces Promotion of Matt Stuttle to Position of Vice President, US Sales
8. Electronic Healthcare Network Announces Multi-State Expansion, Beginning in Buffalo, NY
9. Association of Gaming Equipment Manufacturers (AGEM) Announces $100,000 in Contributions to Organizations Working to Assist Problem Gamblers
10. American DG Energy Announces $3.5 Million Private Placement
11. Brookdale Announces Second Quarter 2009 Release and Earnings Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 Lauren Collura, a mother of ... “Back to the Boardwalk” Facebook sweepstakes. Lauren, her husband, and ... four-bedroom beachfront house in Lavallette beginning this Saturday. , ... Boardwalk” sweepstakes. Last year, Horizon Blue Cross Blue Shield of ... Superstorm Sandy and decided to make it a new summer ...
(Date:8/21/2014)... 21, 2014 American Addiction Centers, a ... for individuals with drug and/or alcohol addiction, has been ... Growing Private Companies. , The company is ranked 7th ... list and 4th on the list in the “Nashville ... of 995%, American Addiction Centers (AAC) ascended to number ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Using two types ... the disease and may boost efforts to eradicate polio, ... 1,000 children in India found that giving the Salk ... been given the Sabin live-attenuated oral poliovirus vaccine (OPV) ... causes polio. The findings, reported in the Aug. ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pleio, ... adherence, is launching a new suite of services ... offerings assist retail pharmacy by applying proven behavior ... classes, resulting in increased medication adherence, higher PDC ... As such, Pleio’s PDC-targeted offerings align retail’s desire ...
(Date:8/21/2014)... developed a way to use a laser to measure ... the laser system to a portable size, the technique ... themselves to draw blood. , "We are working hard ... to use in their daily lives," said Claire Gmachl, ... project,s senior researcher. "With this work we hope to ...
Breaking Medicine News(10 mins):Health News:American Addiction Centers Named to Inc. 500 List Recognition for Three-Year Sales Growth of 995% 2Health News:Two Polio Vaccines May Give Greater Protection Against Crippling Disease 2Health News:Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy 2Health News:Laser device may end pin pricks, improve quality of life for diabetics 2Health News:Laser device may end pin pricks, improve quality of life for diabetics 3
... obese men because the telltale blood marker used to detect ... population, according to a new study led by Duke Prostate ... their bodies than normal weight men, and as a result, ... -- the gold standard for detecting prostate cancer -- can ...
... The extra blood volume produced in the obese may so ... the popular PSA test may be essentially useless for diagnosing ... in The Journal of the American Medical Association suggests. ... 13,000 prostate cancer patients at The Johns Hopkins Hospital and ...
... first reliable follow-up for patients after treatment, researchers ... Whole-body positron emission tomography (PET) scans three months ... help determine whether they,re cancer-free or require further ... difficult to determine if treatment has eliminated cervical ...
... survival of very sick children, study finds , , TUESDAY, ... team of experts at a children,s hospital can cut ... outside the intensive care unit, a new study suggests. ... improvement in mortality, so that adds to the potential ...
... offers formulas of essential prenatal ... ... Mission Pharmacal today announced,the launch of the CitraNatal(TM) family of ... of essential vitamins,and minerals for women prior to conception, throughout ...
... Kelle Ilitch, an,entrepreneur trained in Pilates, is bringing the ... boutique, Pure Element Pilates.,Ilitch,s version of the innovative barre ... weights, Pilates and dance exercises,in rapid sequence to tone ... available at any other studios in the area. ...
Cached Medicine News:Health News:Study suggests adjusting PSA scores for obese men or cancers may be missed 2Health News:Obesity-linked high blood volumes render PSA prostate cancer test less effective, study suggests 2Health News:PET Scans Can Spot Cervical Cancer's Return 2Health News:Rapid Response Teams Can Save Hospitalized Kids 2Health News:Rapid Response Teams Can Save Hospitalized Kids 3Health News:Mission Pharmacal Launches CitraNatal(TM) Prescription Prenatal Vitamin Line 2Health News:Ilitch Brings New Brand of Pilates to Metro Detroit With Opening of Studio in West Bloomfield 2Health News:Ilitch Brings New Brand of Pilates to Metro Detroit With Opening of Studio in West Bloomfield 3
(Date:8/21/2014)... FLORHAM PARK, N.J. , Aug. 21, 2014 ... specialty pharmacy group purchasing organization (GPO), is pleased ... (Aurora) to collaborate on a host of innovative ... will help Aurora deliver enhanced therapy management services ... Therapy Management (OTM) system. Aurora will ...
(Date:8/21/2014)... HOUSTON , Aug. 21, 2014 ... innovation in paediatric medicine by awarding the three ... Paediatric Formulation initiative (EuPFI) conference . The ... 17 – 18 in Athens, Greece ... by pharmacy students and professionals, from which three ...
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... ... ... - Spasticity Affects a Significant Number of Post-Stroke ... , , ...
... Robbins & Myers, Inc. (NYSE: RBN ) announced today that its Board of Directors approved a regular cash dividend payment of $0.0425 per share. , ... , , ... ... The dividend is payable on May 7, 2010 to shareholders of record as of ...
Cached Medicine Technology:First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 2First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 3First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 4First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 5First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 6First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 7First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 8First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 9
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Alkaline Phosphatase in serum or plasma....
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: